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Inhibition of LtxA Toxicity by Blocking Cholesterol Binding With Peptides
Abstract
The leukotoxin (LtxA) produced by Aggregatibacter actinomycetemcomitans kills host immune cells,
allowing the bacterium to establish an ecological niche in the upper aerodigestive tract of its human host.
The interaction of LtxA with human immune cells is both complex and multifaceted, involving membrane
lipids as well as cell-surface proteins. In the initial encounter with the host cell, LtxA associates with
lymphocyte function-associated antigen-1 (LFA-1), a cell surface adhesion glycoprotein. However, we
have also demonstrated that the toxin associates strongly with the plasma membrane lipids, specifically
cholesterol. This association with cholesterol is regulated by a cholesterol recognition amino acid
consensus (CRAC) motif, with a sequence of 334LEEYSKR340, in the N-terminal region of the toxin. Here,
we have demonstrated that removal of cholesterol from the plasma membrane or mutation of the LtxA
CRAC motif inhibits the activity of the toxin in THP-1 cells. To inhibit LtxA activity, we designed a short
peptide corresponding to the CRAC336 motif of LtxA (CRAC336WT). This peptide binds to cholesterol and
thereby inhibits the toxicity of LtxA in THP-1 cells. Previously, we showed that this peptide inhibits LtxA
toxicity against Jn.9 (Jurkat) cells, indicating that peptides derived from the cholesterol-binding site of
LtxA may have a potential clinical applicability in controlling infections of RTX-producing organisms.
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Summary

Author Manuscript

The leukotoxin (LtxA) produced by Aggregatibacter actinomycetemcomitans kills host immune
cells, allowing the bacterium to establish an ecological niche in the upper aerodigestive tract of its
human host. The interaction of LtxA with human immune cells is both complex and multifaceted,
involving membrane lipids as well as cell-surface proteins. In the initial encounter with the host
cell, LtxA associates with lymphocyte function-associated antigen-1 (LFA-1), a cell surface
adhesion glycoprotein. However, we have also demonstrated that the toxin associates strongly
with the plasma membrane lipids, specifically cholesterol. This association with cholesterol is
regulated by a cholesterol recognition amino acid consensus (CRAC) motif, with a sequence
of 334LEEYSKR340, in the N-terminal region of the toxin. Here, we have demonstrated that
removal of cholesterol from the plasma membrane or mutation of the LtxA CRAC motif inhibits
the activity of the toxin in THP-1 cells. To inhibit LtxA activity, we designed a short peptide
corresponding to the CRAC336 motif of LtxA (CRAC336WT). This peptide binds to cholesterol and
thereby inhibits the toxicity of LtxA in THP-1 cells. Previously, we showed that this peptide
inhibits LtxA toxicity against Jn.9 (Jurkat) cells, indicating that peptides derived from the
cholesterol-binding site of LtxA may have a potential clinical applicability in controlling
infections of RTX-producing organisms.
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Introduction
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The pathogenicity of Aggregatibacter actinomycetemcomitans is regulated by a number of
virulence factors (Fives-Taylor et al., 1999), including a leukotoxin (LtxA) that selectively
kills human immune cells (Taichman et al., 1987), allowing the organism to colonize the
host. As a member of the repeats-in-toxin (RTX) family of protein toxins (Welch, 1991),
LtxA shares with this family the common RTX operon organization, which includes five
genes that regulate the translation and secretion of the toxin. The leukotoxin operon contains
four genes, ltxCABD, where ltxA encodes the inactive protein (proLtxA), ltxC encodes an
acyltransferase that posttranslationally activates the protoxin (Balashova et al., 2009; Fong
et al., 2011; Hackett et al., 1994; Hardie et al., 1991; Issartel et al., 1991), and ltxB and ltxD,
along with a fifth gene, tdeA (Crosby and Kachlany, 2007), located 572 kb downstream of
the ltx operon, produce proteins involved in the secretion of the activated toxin in a Type I
secretion system (Kanonenberg et al., 2013).

Author Manuscript

The mechanism by which LtxA kills cells is congruent with a wide variety of bacterial
protein toxins, whereby target cell recognition initiates a multi-step process that culminates
in cell death (Isberg and Tran Van, 1994; London, 1992; Merritt and Hol, 1995; Parker et
al., 1990; Van Rie et al., 1989). RTX toxins vary in their target cell specificity, and have
historically been classified as either hemolysins or leukotoxins. The RTX hemolysins, such
as Escherichia coli α-hemolysin (Cavalieri et al., 1984), and Actinobacillus
pleuropneumoniae ApxIA (Frey et al., 1991) are broadly toxic to a wide variety of cell types
derived from many species, while the leukotoxins are much more restrictive in their toxicity.
As an RTX leukotoxin, the A. actinomycetemcomitans LtxA specifically kills immune cells
from man, the Great Apes, and Old World monkeys (Taichman et al., 1984; Taichman et al.,
1987) that express the β2 integrin, lymphocyte function-associated antigen-1- (LFA-1)
(Kieba et al., 2007; Lally et al., 1997). Other RTX toxins, including Bordetella pertussis
adenylate cyclase toxin and the Mannheimia haemolytica LktA, have been found to bind to
β2 integrins as well (Atapattu and Czuprynski, 2007; Bumba et al., 2010). The exclusive
association of these bacteria with their respective hosts has possibly been driven by parallel
evolution of their respective rtxA genes, with the result being the high degree of target cell
specificity that we now observe.
In addition to these specific receptor interactions, LtxA and the RTX cytotoxins are highly
membrane-active, with a demonstrated effect on the packing of the plasma membrane lipids
(Barcena-Uribarri et al., 2015; Brown et al., 2012; Martin et al., 2004) and a clustering of
the toxin and their integrin receptor in cholesterol-enriched lipid rafts (Atapattu and
Czuprynski, 2007; Bumba et al., 2010; Fong et al., 2006).
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Examination of the deduced amino acid sequences of LtxA and several RTX toxins revealed
that they contain cholesterol recognition amino acid consensus (CRAC) motifs (Brown et
al., 2013). We demonstrated that in LtxA, one of these motifs, CRAC336, is responsible for
the cholesterol binding by LtxA that regulates the lipid raft clustering. In the
characterization of the CRAC motif in LtxA, we discovered that a peptide derived from the
CRAC sequence of LtxA is able to bind to cholesterol and inhibit LtxA binding to
cholesterol. Recently, using molecular dynamics simulations, we have demonstrated that this
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CRAC peptide interacts strongly with membranes containing 40% cholesterol and that this
association results in a decrease in secondary structure in the peptide, which is not observed
in the absence of cholesterol (Miller et al., 2014).
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In the current work, we have explored the possibility of inhibiting LtxA binding to
cholesterol as a means of inhibiting activity. We found that the interaction between LtxA
and cholesterol is highly specific, requiring both an intact CRAC sequence and a specific
sterol structure, and disruption of this interaction in a number of different ways is sufficient
to inhibit LtxA toxicity. We inhibited the association of LtxA with cholesterol in the target
cell plasma membrane by removing cholesterol with methyl-β-cyclodextrin (mβCD),
preincubating LtxA with cholesterol-containing liposomes, and blocking plasma membrane
cholesterol with a cholesterol-binding peptide. All three methods significantly reduced the
ability of LtxA to kill THP-1 cells, demonstrating the potential therapeutic use of inhibition
of cholesterol-binding by LtxA to minimize cytotoxicity.

Methods
Chemicals
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased from Avanti
Polar Lipids (Alabaster, AL). Cholesterol (Chol), methyl-β-cyclodextrin (MβCD), and
methyl-β-cyclodextrin-cholesterol (MβCD-Chol) were purchased from Sigma-Aldrich (St.
Louis, MO), and ergosterol (Ergo) was purchased from MP Biomedicals (Solon, OH).
Peptides were synthesized and purified (98% purity) by Biomatik (Wilmington, DE).
LtxA purification

Author Manuscript

A. actinomycetemcomitans strain JP2 was grown overnight in AAGM broth (Fine et al.,
1999) supplemented with 12.5 μg/ml vancomycin and 75 μg/ml bacitracin. LtxA was
purified as described previously (Kachlany et al., 2002). The purity of the toxin was
confirmed by SDS-PAGE and Western blot, and the activity was confirmed using a
cytotoxicity assay. To inactivate LtxA, the toxin was heated at 65 °C for 30 mins.

Author Manuscript

Production of the CRAC mutant, LtxAY336P, was accomplished in E. coli using a pSHH
plasmid containing the ltxA-promoter region, ltxC, and the mutated ltxA genes (Brown et al.,
2013). The CRAC mutant was constructed by substituting proline for tyrosine at amino acid
position 336 through site-directed mutagenesis, performed using a QuikChange® sitedirected mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA), according to the
manufacturer's instructions. The primers containing the substitutions were designed using
the OligoPerfect™ Designer, as shown previously (Brown et al., 2013). The reactions were
performed on an automated thermal cycler with an initial step of 30 s at 95 °C, followed by
PCR amplification for 16 cycles of 30 s at 95 °C, 1 min at 55 °C, and 3 min at 68 °C. The
obtained PCR products were transformed into DH5α-T1 cells, and the mutant clones were
selected on LB agar plates with 50 μg/ml of ampicillin. The LtxAY336P mutant is
constitutively expressed in the cytosol. To collect this protein, 200 mL of LB supplemented
with ampicillin (50 μg/mL) was inoculated with overnight cultures of the E. coli DH5α-T1
mutant clones and then grown to an OD600 of approximately 0.4. The cultures were
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centrifuged and resuspended in 6 mL of buffer (20 mM Tris-HCl, 250 mM NaCl, 0.2 mM
CaCl2, pH 6.8), sonicated (six times for 45 s, on ice), and centrifuged to remove the cell
debris (12,000 × g, 15 min, 4 °C).
Liposome Preparation

Author Manuscript

Liposomes composed of POPC and cholesterol were prepared using the lipid film technique.
Stock solutions of POPC and cholesterol (both 25 mg/mL) were prepared in chloroform and
then added to a glass vial in the required amounts. The chloroform was evaporated under a
stream of nitrogen, and the residual chloroform was removed under vacuum to create a thin
lipid film on the glass surface. Multilamellar liposomes (MLVs) were created by hydrating
the lipid film with PBS. Liposomes composed of POPC and ergosterol were formed using
the rapid solvent exchange (RSE) technique (Buboltz and Feigenson, 1999). Stock solutions
of POPC and ergosterol were added to a glass vial, PBS was added directly, and the
chloroform was evaporated while the solution was vortexed. Large unilamellar vesicles
(LUVs) were formed from all MLV solutions by extrusion (MacDonald et al., 1991) through
a 100 nm polycarbonate Whatman membrane (GE Healthcare Bio-Sciences, Pittsburgh, PA)
35 times with a LiposoFast® extruder (AVESTIN Inc., Ottawa, ON).
Cell culture
THP-1 cells obtained from ATCC were maintained in RPMI 1640 medium containing 10%
FBS and 0.05 mM 2-mercaptoethanol at 37 °C under 5% CO2.
Immunofluorescence
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LtxA was labeled with the DyLight® 647 Amine-Reactive dye (Thermo Scientific™),
according to the manufacturer's instructions with some modifications. Specifically, the toxin
was purified from an excess of the dye using a 40k MWCO Zeba Spin Desalting column
(Thermo Scientific™).
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For the LtxA binding studies 0.5 × 106 THP-1 cells/mL were washed with live cell imaging
solution (LCIS) (Thermo Scientific™), and the cell nuclei were stained with 5 μM Hoescht
33342 for 15 min (Thermo Scientific™). The cells were then placed for 20 min in ibiTreat
60 μ-dishes (Ibidi) coated with poly-L-lysine (Sigma-Aldrich®). The attached cells were
covered with 1 mL LCIS and were examined using a Nikon A1R laser scanning confocal
microscope with a 60× water objective (NA 1.2). After the dish was adjusted in the
microscope stage, the initial image was collected, and then 20 ng of LtxA was carefully
added to the cells and the following images of the same area were collected for 30 min. The
images were processed using Nikon's Elements® software 4.1. Approximately 50 cells per
image were analyzed in each experiment to identify the mean fluorescence intensities by
sorting cell-associated areas in 3 combined Z planes collected for each image.
Depletion and Replenishment of Plasma Membrane Cholesterol Levels
THP-1 cells, maintained in cell culture media, were depleted of cholesterol through
incubation with 10 mM MβCD for 15 minutes at 37 °C and 5% CO2. After the incubation,
the cells were washed with cell culture media to remove any excess MβCD and were used in
the cytotoxicity assay immediately. To replenish cholesterol, some of the MβCD-treated
Mol Oral Microbiol. Author manuscript; available in PMC 2017 February 01.
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cells were subjected to an additional incubation with 1 mM MβCD-Chol for 1 hr at 37 °C
and 5% CO2. These cholesterol-replenished cells were then washed and used immediately.
The concentration of cholesterol in the THP-1 cell membranes before depletion, after
depletion, and after replenishment was measured with an Amplex® Red Cholesterol Assay
Kit (Life Technologies™). Intensity measurements were performed with an Infinite 200 Pro
plate reader (Tecan Group Ltd., Männedorf, Switzerland) with an excitation wavelength of
555 nm and an emission wavelength of 580 nm.
Cytotoxicity assays

Author Manuscript
Author Manuscript

For the cytotoxicity tests, LtxA-containing samples were added to THP-1 cells (1 × 106
cells/mL) and incubated for 3 h. The cell membrane permeability was determined with a
trypan blue assay using an automated cell counter. Each experiment was performed three
independent times. Untreated cells were used as a control. (A) To determine the role of
cholesterol in toxicity, cholesterol-depleted and –replenished cells were incubated with 2 μg
of LtxA for 3 hr. Untreated cells, as well as cholesterol-depleted and -replenished cells that
had not been treated with LtxA, were used as controls. (B) In the case of the LtxA CRAC
mutant, 50 μg of total protein in the E. coli cytosolic fraction was added to the THP-1 cells
and incubated for 3 hr. An E. coli DH5α-T1 cytosolic fraction that did not contain pSHH
served as a control. (C) To measure the protective effect of cholesterol-containing
liposomes, the THP-1 cells were incubated with (i) LtxA (ii) LtxA + 100% POPC
liposomes, (iii) LtxA + 60%POPC/40%Chol liposomes, or (iv) LtxA + 60%POPC/40%Ergo
liposomes. The mass of LtxA in each sample was 2 μg, and all liposome concentrations were
9.0 × 10-7 M. Controls included PBS, 100% POPC liposomes alone, 60%POPC/40%Chol
liposomes alone, and 60%POPC/40%Ergo liposomes alone. (D) To measure the protective
effect of the CRAC peptide, THP-1 cells were incubated with protein samples containing (i)
LtxA (ii) LtxA + CRAC336WT or (iii) LtxA + CRAC336SCR. The mass of LtxA in each
sample was 2 μg, and the molar LtxA:peptide ratio was 1:100. Controls included PBS,
CRAC336WT alone, and CRAC336SCR alone.
The percentage of cells alive after each treatment was calculated using the following
equation:

Author Manuscript

where N0 is the number of cells before treatment, and N3 is the number of cells after 3 hours
of treatment.
Peptide Binding Assay
To measure the binding of the CRAC336WT and CRAC336SCR peptides to cholesterol, a
centrifugation assay was performed (Sophianopoulos et al., 1978). The peptides (7.0 × 10-5
M) were incubated with 100% POPC or 60%POPC/40%Chol liposomes at a lipid-to-protein
ratio of 100:1 for 30 min, then added to a centrifugal filter (Amicon® 30k MWCO, EMD
Millipore, Billerica, MA) and centrifuged for 1 h at 6,000 × g (Voglino et al., 1999; Voglino
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et al., 1998). The unbound peptide concentrations were determined by comparing the
intrinsic fluorescence of the eluate at 305 nm to a set of standards of the same peptide with
known concentrations. The fluorescence measurements were recorded on a Quantamaster®
400 spectrofluorometer (PTI Horiba, Edison, NJ) using an excitation wavelength of 281 nm.
The bound peptide concentrations were then calculated from the total and free
concentrations of peptide.
Statistical Analysis
Statistical analysis of the data was performed using OriginPro® 2015 (OriginLab,
Northampton, MA) using one-way ANOVA, followed by a Tukey test. In cases where P >
0.05, we reported no statistically significant difference between the two data sets in
question.
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Results
LtxA associates with the THP-1 cell surface

Author Manuscript

We investigated the process of LtxA binding to THP-1 cells, which express active LFA-1 on
their surface (DiFranco et al., 2012) and are highly susceptible to LtxA (Kachlany et al.,
2010). Active and heat-inactivated LtxA was labeled with DyLight® 647 for confocal
imaging. When active DyLight® 647- LtxA (20 ng) was added to THP-1 cells in a timelapse live confocal imaging experiment, binding of the toxin to the surface of most of the
cells was observed within 5 min (Fig. 1A), as indicated by blue fluorescent dots
accumulating on the cell membrane and presented as mean fluorescence intensity (Fig. 1B).
In contrast, significantly less binding was detected when the same amount of the heatinactivated (HI) DyLight® 647-LtxA was applied to THP-1 cells, even after a 30-min
incubation, suggesting that HI-LtxA was inhibited in its ability to interact with the
membrane.
LtxA toxicity is dependent on the presence of cholesterol

Author Manuscript

The association of LtxA with the membrane suggests that the toxin may interact with the
cell plasma membrane lipids. Previously, we found that LtxA must bind to cholesterol on
the Jurkat (Jn.9) cell plasma membrane to kill the cells (Brown et al., 2013). To investigate
whether LtxA binding to the THP-1 membrane is likewise regulated by the presence of
cholesterol, we extracted cholesterol from the THP-1 plasma membrane using MβCD and
found that the toxicity of LtxA was significantly diminished in the absence of cholesterol
(Fig. 2). When the plasma membrane was replenished with cholesterol, using MβCD
followed by MβCD-Chol, the cells again became susceptible to LtxA, indicating that the
interaction of LtxA with cholesterol on the THP-1 plasma membrane is an essential element
of the toxin's mechanism of action. One-way ANOVA followed by a Tukey test indicated
that the cholesterol-dependence of LtxA activity is statistically significant (Table 2).
Neither treatment with MβCD nor treatment with MβCD followed by MβCD-Chol was toxic
over the time course of the experiment (data not shown). The actual cholesterol
concentrations in the cell membrane before and after MβCD treatment was determined using
an Amplex® Red Cholesterol Assay. Untreated cells had a cholesterol concentration of
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112.01 + 1.87 μM, and after treatment with MβCD, the cholesterol concentration decreased
67.6% to 36.38 + 1.34 μM. Replenishment of cholesterol with MβCD-Chol restored the
cholesterol concentration to near original levels, 104.88 + 1.34 μM.
LtxA toxicity is regulated by an intact cholesterol-binding site

Author Manuscript

Previously, we demonstrated that a CRAC motif regulates the binding of LtxA to Jn.9 cells
and the resulting toxicity. To confirm that this same CRAC336 motif regulates cholesterol
binding in THP-1 cells as well, we induced a point mutation (Y336 -> P336) in the ltxA
CRAC336 site using site-directed mutagenesis. The wild-type and mutant ltxA genes were
cloned into pSHH and expressed in tandem with the ltxC gene, under the control of the wildtype promoter. The proteins were constitutively expressed in the cytosol of E. coli. The
bacterial suspensions were sonicated, and the supernatants were collected and normalized by
the total protein concentration. These normalized supernatants were then incubated with
THP-1 cells, and the cytotoxicity was measured using a trypan blue assay. We have
previously demonstrated that LtxACRACY336P is stable and produced at comparable levels to
that of LtxAWT (Brown et al., 2013).
As shown in Fig. 3, after 24 h of exposure to the E. coli supernatants, cells exposed to
LtxAWT had a very low viability relative to those exposed to a blank control. Cells exposed
to the LtxACRACY336P mutant remained viable during the time scale of the experiment,
indicating that, as in Jn.9 cells, the CRAC336 site is essential for the toxicity of LtxA in
THP-1 cells. This result suggests that LtxA binds to cholesterol on the THP-1 plasma
membrane during its initial interaction with the cell.
Inhibition of binding to cholesterol inhibits LtxA toxicity

Author Manuscript

We investigated the possibility of blocking the binding of LtxA to cholesterol on the target
cell plasma membrane as a means to inhibit the toxin's activity by preincubating the toxin
with liposomes composed of POPC and 40% cholesterol. First, we incubated LtxA with
cholesterol-containing liposomes before incubating the mixture with THP-1 cells, with the
idea that the LtxA would bind to cholesterol on the liposome and therefore be unable to bind
to cholesterol on the cell membrane. Fig. 4 demonstrates that this approach was successful.
THP-1 cells were susceptible to free LtxA; however, when the LtxA was preincubated with
POPC/Chol liposomes, the cells remained viable throughout the experiment.

Author Manuscript

To determine the specificity of this inhibition, we repeated the experiment using two types
of liposomes that did not contain cholesterol, 100% POPC liposomes and 60%POPC/
40%Ergo liposomes. Ergo is a sterol found in yeast and other fungal membranes that differs
in structure from cholesterol in both the ring and tail domains. As shown in Fig. 4, neither
type of liposome was able to inhibit LtxA toxicity, demonstrating that the binding of LtxA
to cholesterol is specific to this particular lipid and suggesting that inhibiting the binding of
LtxA to cholesterol could be an effective approach to alter LtxA activity. The specificity of
this interaction was statistically significant as determined by a one-way ANOVA followed
by a Tukey test (Table 2).

Mol Oral Microbiol. Author manuscript; available in PMC 2017 February 01.

Brown et al.

Page 8

Cholesterol-binding peptides inhibit LtxA toxicity

Author Manuscript

We next investigated the possibility of inhibiting LtxA activity using a cholesterol-binding
peptide derived from the CRAC336 site of LtxA. A cholesterol-binding peptide
(CRAC336WT), consisting of the CRAC336 sequence of LtxA with six flanking residues on
either side, and a scrambled control (CRAC336SCR), in which the CRAC motif was
scrambled were synthesized for this purpose. The sequences of the two peptides are shown
in Table 1. An analytical centrifugation assay was used to demonstrate that the CRAC336WT
peptide binds more effectively to liposomes containing 40% cholesterol than it does to those
without cholesterol (Fig. 5), indicating that this peptide binds specifically to cholesterol in
the liposome. Additionally, the CRAC336WT peptide bound to a greater extent to the 40%
cholesterol liposomes than did the CRAC336SCR peptide, demonstrating that, as in the fulllength toxin, the intact CRAC sequence is essential for this binding. The results of a
statistical analysis of this data are included in Table 2.

Author Manuscript

This binding experiment was repeated with multiple liposome concentrations and the half
maximal effective liposome concentration (EC50) and the liposome saturation limit of
CRAC336WT binding to POPC/Chol liposomes were determined using a sigmoidal fit of the
data. The results of this fit predict an EC50 of 3.2 μM and a saturation limit, representing
100% binding of the peptide to the liposomes, of 73.5 mM.

Author Manuscript

To inhibit LtxA binding to cholesterol and the resulting toxicity, we incubated THP-1 cells
with LtxA alone or in combination with the CRAC336WT peptide or the CRAC336SCR
peptide. As shown in Fig. 6, The CRAC336WT peptide, but not the CRAC336SCR peptide,
inhibited the activity of LtxA almost completely. A statistical analysis of these results is
included in Table 2. Neither peptide was toxic to the cells at the concentrations used over the
time course of the experiment.
To determine the half maximal peptide inhibitory concentration (IC50) and peptide
saturation limit of the CRAC336WT peptide, the experiment was repeated with several
peptide concentrations, and the data were fit to a sigmoidal curve. The results of this fit
predict an IC50 of 6.1 μM and a saturation limit, representing the peptide concentration
resulting in 100% viability of the cells, of 0.0341 mM for the CRAC336WT peptide.
Previously, we demonstrated that the CRAC336WT peptide inhibits LtxA toxicity against Jn.
9 cells (Brown et al., 2013). Therefore, this result demonstrates that an LtxA-derived
cholesterol-binding peptide can be used to specifically alter the binding and subsequent
toxicity of LtxA against several cell types, suggesting that the approach may have broad
applicability in the treatment of A. actinomycetemcomitans infections.
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Discussion
Greater than 90% of cellular cholesterol resides at the plasma membrane and is essential for
cell viability and proliferation (van Meer et al., 2008; Yeagle, 1991). Cholesterol is not
uniformly dispersed throughout biological membranes; rather, it is sequestered in membrane
microdomains known as lipid rafts (Simons and Ikonen, 1997), along with sphingolipids and
specialized proteins, such as glycosylphosphatidylinositol (GPI)-anchored proteins,

Mol Oral Microbiol. Author manuscript; available in PMC 2017 February 01.

Brown et al.

Page 9

Author Manuscript
Author Manuscript

heterotrimeric G protein-coupled receptors, and Src family kinases (Simons and Toomre,
2000; Varma and Mayor, 1998; Chini and Parenti, 2004; Liang et al., 2001). Many
pathogens and their virulence factors have thus developed the ability to recognize and bind
to lipid raft cholesterol on the surface of host cells. For example, cholesterol is required for
the uptake of mycobacteria by host cells (Gatfield and Pieters, 2000) and Leishmania
(Pucadyil and Chattopadhyay, 2007) and allows these intracellular pathogens to avoid
degradation by inhibiting lysosomal-phagosomal fusion (Pieters and Gatfield, 2002). In
addition, the activity of a number of bacterial toxins depends on the presence of cholesterol
in the target membrane (Atapattu and Czuprynski, 2007; Boesze-Battaglia et al., 2006;
Boesze-Battaglia et al., 2009; Brown et al., 2013; Bumba et al., 2010; Farrand et al., 2010;
Fong et al., 2006; Giddings et al., 2004; Lai et al., 2013; Orlandi and Fishman, 1998; Patel
et al., 2002; Schraw et al., 2002; Zhao et al., 2012). Influenza (Sun and Whittaker, 2003),
human immunodeficiency virus type 1 (Guyader et al., 2002; Liao et al., 2004) and the
Ebola virus (Bavari et al., 2002) also require cholesterol in the host membrane for binding to
and/or exit from the cell.
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Previously, we reported that the binding of LtxA to cholesterol occurs with high affinity
(Brown et al., 2013), suggesting the involvement of a lipid-binding site within the toxin.
Several proteins that interact with cholesterol have an amino acid sequence in the
juxtamembrane region conforming to the pattern –L/V-(X1-5)-Y-(X1-5)-R/K-, in which
(X1-5) represents between one and five residues of any amino acid (Li and Papadopoulos,
1998). The stringency of this motif is flexible, and therefore, not all predicted CRAC sites
bind cholesterol or possess an in vivo function. In the deduced amino acid sequence of LtxA,
CRAC336 (334LEEYSKR339) and CRAC503 (502VDYLKK505) were identified as potential
cholesterol binding sites. While both sequences are juxtaposed to hydrophobic domains in
LtxA, only CRAC336 was found to bind to cholesterol and regulate toxicity of LtxA.
CRAC336 is highly conserved among other RTX toxins, suggesting a common cholesterolbinding pathogenesis among the members of the RTX family, although additional studies to
substantiate this are necessary.
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In the current study, we used THP-1, a human monocytic leukemia cell line, which
expresses LFA-1 (DiFranco et al., 2012), to investigate the role of cholesterol binding by
LtxA on its toxicity. While we and others have shown that LtxA cytotoxicity requires the
expression of LFA-1 by the host cell (Kachlany et al., 2010; Kieba et al., 2007; Lally et al.,
1997), we have also shown that LtxA, like other RTX toxins, is strongly membrane-active
(Brown et al., 2012; Brown et al., 2013; Walters et al., 2013) and has a particularly strong
affinity (10-12 M) for membranes containing 40% cholesterol (Brown et al., 2013). This
membrane activity is correlated with subtle conformational changes in the entire protein
structure (Lear et al., 2000; Walters et al., 2013), but a significant decrease in helicity within
the cholesterol-binding domain upon association with cholesterol (Miller et al., 2014),
which allows the protein to move from a water-soluble to a membrane active state.
This work demonstrates the requirement of cholesterol binding by LtxA in cytotoxicity.
Based on this and our previous results, we can conclude that LtxA requires both LFA-1 and
cholesterol to be present on the membrane in order for the toxin to kill the target cells. In
addition, this work suggests that a possible approach to the inhibition of LtxA activity may
Mol Oral Microbiol. Author manuscript; available in PMC 2017 February 01.
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be the blocking of cholesterol binding by the toxin. We are currently investigating the longterm toxicity of this cholesterol-binding peptide to study its possible clinical use as an
alternative to current, toxic approaches to inhibit the activity of cholesterol-binding proteins
and pathogens. Future work will focus on refining the CRAC motif in the peptide to enhance
cholesterol binding and improve inhibition of toxin/pathogen binding.
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Fig. 1. Association of LtxA with THP-1 cells
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A. Confocal images showing the interaction between LtxA and THP-1 cells. The left panel
demonstrates the cell before treatment and the right panel demonstrates the same cell 5 min
after 20 nM DyLight® 647-LtxA (light blue) was added. Cell nuclei were stained with
Hoescht 33342 (dark blue). Arrows demonstrate some areas of toxin binding on the plasma
membrane. Representative images are shown. Scale bar = 5 μm. B. Quantitative
fluorescence intensity analysis of confocal microscopy images indicating association of
LtxA and heat-inactivated (HI)-LtxA with THP-1 cells. Each bar represents the summed
intensity of 55 regions of interest (ROI). A t-test indicates that there is a significant
difference in the binding of LtxA and HI-LtxA after 5 mins. ***, p < 0.001.
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Fig. 2. Cytotoxicity of LtxA after cholesterol extraction from THP-1 cells

The toxicity of LtxA was measured in THP-1 cells as a function of cholesterol composition.
THP-1 cells were either untreated, treated with MβCD for 15 min to extract cholesterol, or
treated with MβCD for 15 min followed by MβCD-Chol for one hr to replenish cholesterol.
Cells with reduced cholesterol compositions were significantly less susceptible to LtxA than
were those with wild type cholesterol levels. Replenishment of cholesterol restored
susceptibility to LtxA. The data represent the averages of three independent experiments,
and the error bars represent the standard deviation. A one-way ANOVA followed by a
Tukey test was used to determine the level of significance between each experiment. ***, p
< 0.001; N.S., Not significant.
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Fig. 3. Mutation of the cholesterol-binding site inhibits LtxA cytotoxicity

Point mutations were induced in ltxA by substituting proline for tyrosine at amino acid
position 336 using site-directed mutagenesis. The wild type ltxA gene and mutant gene were
cloned into pSHH and expressed in tandem with ltxC under the control of the native
leukotoxin promoter. Overnight cultures of LtxA and LtxAY336P were constitutively
expressed in the E. coli DH5α cytosol. E. coli cytosolic fractions containing 50 μg of total
protein were incubated with THP-1 cells for 3 hr. The THP-1 cells were highly susceptible
to LtxAWT sonicates but not to LtxAY336P. A sonicate from E. coli DH5α containing the
pSHH empty vector served as the negative control. Cell death was measured with a trypan
blue assay. ***, p < 0.001; *, p < 0.05.

Author Manuscript
Mol Oral Microbiol. Author manuscript; available in PMC 2017 February 01.

Brown et al.

Page 17

Author Manuscript
Author Manuscript
Author Manuscript

Fig. 4. Pre-binding to cholesterol inhibits LtxA toxicity

LtxA was preincubated with liposomes composed of 60% POPC and 40% Chol for 15 mins
before incubation with THP-1 cells. Preincubation of LtxA with these cholesterol-containing
liposomes completely inhibited the toxicity of LtxA. Preincubation of LtxA with liposomes
without cholesterol, composed of either 100% POPC or 60% POPC/40%Ergo, did not
inhibit LtxA toxicity. A one-way ANOVA followed by a Tukey test was used to determine
the level of significance between each experiment. ***, p < 0.001; **, p < 0.01; N.S., Not
significant.
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Fig. 5. CRAC336WT peptide has a specific affinity for cholesterol

A peptide corresponding to the cholesterol-binding motif in LtxA (CRAC336WT) was
synthesized along with a control peptide in which the cholesterol-binding sequence was
scrambled (CRAC336SCR). The peptides were incubated with liposomes composed of either
100% POPC or 60%POPC/40% Chol for 30 min. Unbound peptide was separated from the
liposome-peptide complexes using a centrifugal filter, and the concentration of unbound
peptide was determined by comparing the fluorescence intensity of the eluate to a set of
standards. CRAC336WT bound significantly more to liposomes containing cholesterol than to
those without cholesterol. CRAC336SCR bound with a lower affinity to the POPC/Chol
liposomes than did CRAC336WT. A one-way ANOVA followed by a Tukey test was used to
determine the level of significance between each experiment. ***, p < 0.001; **, p < 0.01.
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Fig. 6. CRAC336WT peptide inhibits LtxA toxicity

LtxA and either CRAC336WT or CRAC336SCR were incubated with THP-1 cells for 3 hr, and
the viability of the cells was measured using a trypan blue assay. The CRAC336WT peptide,
which binds to cholesterol, inhibited the toxicity of LtxA, but the CRAC336SCR peptide,
which does not bind to cholesterol, did not inhibit LtxA toxicity. A one-way ANOVA
followed by a Tukey test was used to determine the level of significance between each
experiment. ***, p < 0.001; N.S., Not significant.
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Table 1

CRAC Peptide Sequences
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Name

Sequence

CRAC336WT

FDRARMLEEYSKRFKKFGY

CRAC336SCR

FDRARMYEKLERSFKKFGY

The CRAC motif is highlighted in yellow. Each peptide was acetylated at the N-terminus and amidated at the C-terminus.
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Table 2

Summary of statistical comparisons of data

Author Manuscript

Comparison

P value

Significantly Different

Author Manuscript

LtxA

vs.

MβCD + LtxA

0.00008

Yes

LtxA

vs.

MβCD + MβCD -Chol + LtxA

0.07240

No

MβCD + LtxA

vs.

MβCD + MβCD -Chol + LtxA

0.00003

Yes

LtxA

vs.

LtxA + POPC

0.24400

No

LtxA

vs.

LtxA + POPC/Chol

0.00000

Yes

LtxA

vs.

LtxA + POPC/Ergo

0.46400

No

LtxA + POPC

vs.

LtxA + POPC/Chol

0.00225

Yes

LtxA + POPC

vs.

LtxA + POPC/Ergo

0.98300

No

LtxA + POPC/Chol

vs.

LtxA + POPC/Ergo

0.00103

Yes

CRAC336WT + POPC

vs.

CRAC336WT + POPC/Chol

0.00502

Yes

CRAC336WT

vs.

CRAC336scr

+ POPC/Chol

0.00001

Yes

CRAC336WT + POPC/Chol

vs.

CRAC336scr + POPC/Chol

0.00000

Yes

LtxA

vs.

LtxA + CRAC336WT

0.00000

Yes

LtxA

vs.

LtxA +

CRACSCR336

0.24800

No

LtxA + CRAC336WT

vs.

LtxA + CRACSCR336

0.00001

Yes

+ POPC

One-way ANOVA was performed using the Tukey comparisons test within OriginPro 2015.
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